RGRX (Regenerx Biopharmaceuticals) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenerx Biopharmaceuticals  (OTCPK:RGRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.14 21.77 90.08 57.97 217.03

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.29 84.70 110.24 190.27 150.00

RGRX vs MYMX, RGMP, NBRVF: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Regenerx Biopharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Regenerx Biopharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=0.013/301.8360*301.8360
=0.013

Current CPI (Mar. 2023) = 301.8360.

Regenerx Biopharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 0.000 233.504 0.000
201309 0.000 234.149 0.000
201312 0.000 233.049 0.000
201403 0.000 236.293 0.000
201406 0.000 238.343 0.000
201409 0.000 238.031 0.000
201412 0.000 234.812 0.000
201503 0.039 236.119 0.050
201506 0.005 238.638 0.006
201509 0.005 237.945 0.006
201512 0.009 236.525 0.011
201603 0.054 238.132 0.068
201606 0.010 241.018 0.013
201609 0.010 241.428 0.013
201612 0.012 241.432 0.015
201703 0.010 243.801 0.012
201706 0.010 244.955 0.012
201709 0.000 246.819 0.000
201712 0.016 246.524 0.020
201803 0.017 249.554 0.021
201806 0.010 251.989 0.012
201809 0.016 252.439 0.019
201812 0.015 251.233 0.018
201903 0.015 254.202 0.018
201906 0.015 256.143 0.018
201909 0.015 256.759 0.018
201912 0.015 256.974 0.018
202003 0.014 258.115 0.016
202006 0.014 257.797 0.016
202009 0.014 260.280 0.016
202012 0.014 260.474 0.016
202103 0.014 264.877 0.016
202106 0.014 271.696 0.016
202109 0.013 274.310 0.014
202112 0.013 278.802 0.014
202203 0.013 287.504 0.014
202206 0.013 296.311 0.013
202209 0.013 296.808 0.013
202212 0.013 296.797 0.013
202303 0.013 301.836 0.013

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.